Primo Chemicals Q4 FY26: Profitability Recovery Masks Persistent Valuation Concerns

The March 2026 quarter showcased a company navigating through challenging market conditions whilst attempting to stabilise operations. Net sales stood at ₹144.86 crores, representing a modest 3.37% sequential improvement but a concerning 6.79% year-on-year decline. This divergence between quarterly momentum and annual trajectory underscores the volatility plaguing the commodity chemicals sector, where pricing pressures and demand fluctuations continue to test operational resilience.

The quarter's profitability turnaround, whilst encouraging on the surface, warrants closer examination. The standalone net profit of ₹5.09 crores marks a significant recovery from the previous quarter's loss of ₹0.34 crores, yet the company's reliance on other income—which contributed ₹5.65 crores or 72.34% of profit before tax—raises questions about the quality and sustainability of earnings. This dependency on non-operating income has emerged as a persistent concern flagged by financial analysts tracking the company's performance.

Financial Performance: A Tale of Two Narratives

Primo Chemicals' Q4 FY26 results present a complex financial picture that defies simple characterisation. On a sequential basis, the company demonstrated meaningful improvement across key metrics. Revenue climbed 3.37% from ₹140.14 crores in Q3 FY26 to ₹144.86 crores, whilst operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) surged 40.07% from ₹13.58 crores to ₹19.02 crores. The operating margin excluding other income expanded to 13.13%, up from 9.69% in the preceding quarter, signalling improved operational efficiency.

However, the year-on-year comparison reveals a more sobering reality. Net sales contracted 6.79% from ₹155.42 crores in Q4 FY25, whilst operating profit excluding other income plunged 20.64% from ₹23.97 crores. The operating margin compression of 231 basis points year-on-year—from 15.42% to 13.13%—reflects the pricing pressures and cost challenges that have characterised the commodity chemicals landscape over the past year. Interest costs declined to ₹3.88 crores from ₹5.78 crores year-on-year, providing some relief, but depreciation remained elevated at ₹12.98 crores.

The tax expense of ₹2.73 crores at an effective rate of 34.91% appears more normalised compared to the previous quarter's anomalous 261.90% rate, though it remains elevated compared to historical averages. Employee costs showed discipline, declining to ₹11.47 crores from ₹12.87 crores year-on-year, suggesting management's focus on cost optimisation amidst revenue headwinds.

Operational Challenges: Margin Pressure and Volume Volatility

The caustic soda industry, in which Primo Chemicals operates as a significant northern India player, has faced considerable headwinds over the past year. The company's membrane cell technology-based production facilities at Naya Nangal have contended with fluctuating raw material costs and subdued pricing power, reflected in the year-on-year margin compression. The operating margin excluding other income peaked at 15.42% in Q4 FY25 before declining through subsequent quarters, touching a low of 9.69% in Q3 FY26, before recovering to 13.13% in the latest quarter.

Return on capital employed (ROCE) has deteriorated significantly, standing at just 4.78% for the latest period compared to a five-year average of 14.04%. This sharp decline indicates that the company's capital is generating substantially lower returns, a worrying trend for a capital-intensive chemicals manufacturer. Similarly, return on equity (ROE) has compressed to 2.54% from the five-year average of 14.79%, signalling diminished shareholder value creation. These metrics underscore the operational pressures facing the business, where invested capital is not yielding commensurate returns.

On a more positive note, the company has demonstrated improved financial discipline. The debt-to-equity ratio reached its lowest level at 0.32 times on a half-yearly basis, whilst the operating profit to interest coverage ratio climbed to a robust 4.90 times in Q4 FY26—the highest in recent quarters. The debtors turnover ratio also improved to 17.66 times, suggesting better working capital management and faster collection cycles. Long-term debt declined to ₹79.98 crores as of March 2025 from ₹106.15 crores a year earlier, reflecting deleveraging efforts.

The Other Income Dependency: A Structural Concern

Perhaps the most troubling aspect of Primo Chemicals' Q4 FY26 performance lies in the composition of profitability. With other income of ₹5.65 crores accounting for 72.34% of profit before tax of ₹7.82 crores, the company's core manufacturing operations generated profit before tax excluding other income of merely ₹2.16 crores. This represents a significant improvement from the previous four-quarter average, having grown at 1,083.6%, but the absolute quantum remains modest relative to the company's ₹609.25 crore market capitalisation.

This structural dependency on non-operating income is not a new phenomenon for Primo Chemicals. Examining annual data, other income contributed ₹20.00 crores in FY25 against operating profit excluding other income of ₹68.00 crores, suggesting that whilst the reliance exists, it was less pronounced on an annual basis. However, the quarterly volatility in other income—ranging from ₹4.41 crores to ₹5.86 crores over recent quarters—adds an element of unpredictability to earnings forecasts.

Investors must scrutinise the sources of this other income. Typically, such income streams from treasury operations, dividend receipts from investments, or one-time gains from asset sales. The company's investments stood at ₹60.64 crores as of March 2025, up from ₹59.43 crores, which could be generating returns. However, without greater transparency on the composition and sustainability of other income, assigning a premium valuation to reported earnings becomes problematic.

Peer Comparison: Valuation Disconnect

Primo Chemicals' valuation metrics present a stark contrast to its commodity chemicals peers, revealing a significant disconnect between market pricing and fundamental performance. The company trades at a price-to-earnings ratio of 68.01 times trailing twelve-month earnings, dramatically higher than the industry average of approximately 15 times and multiples above most direct competitors.

This premium valuation appears unjustified when examining operational performance. Primo Chemicals' ROE of 14.79% lags the peer average and falls dramatically short of Tuticorin Alkali's exceptional 71.21%. The company's price-to-book ratio of 1.55 times sits in the middle of the peer range, neither commanding a premium nor trading at a discount that would suggest value opportunity. Notably, Primo Chemicals does not pay dividends, whilst several peers offer yields ranging from 0.37% to 1.69%, providing investors with tangible cash returns.

The elevated P/E multiple of 68.01 times becomes particularly difficult to justify given the company's modest growth profile and deteriorating return metrics. With sales growth of 11.63% over five years and recent quarterly revenue declining year-on-year, the premium to peers like Sr.Rayala.Hypo (8.82x P/E) or Transpek Industries (11.31x P/E) lacks fundamental support. This valuation disconnect suggests either market inefficiency or expectations of a dramatic operational turnaround that has yet to materialise in reported numbers.

Valuation Analysis: Premium Without Justification

At the current market price of ₹25.14, Primo Chemicals trades at multiples that appear divorced from underlying business fundamentals. The P/E ratio of 68.01 times stands at more than five times the industry average of 13 times, whilst enterprise value to EBITDA of 10.54 times and enterprise value to sales of 1.35 times suggest the market has priced in expectations that current operational performance does not support.

The company's book value per share stands at ₹14.72, implying a price-to-book ratio of 1.71 times at the current market price. For a business generating ROCE of just 4.78% and ROE of 2.54%—both well below the cost of capital—this premium to book value appears difficult to rationalise. Typically, companies earning returns below their cost of capital trade at discounts to book value, not premiums, as they are destroying rather than creating shareholder value.

The stock's 52-week range of ₹16.21 to ₹31.44 reflects significant volatility, with the current price sitting 20.04% below the high and 55.09% above the low. This wide trading range underscores investor uncertainty about the company's trajectory and fair value. The valuation grade of "Attractive" assigned by proprietary models appears to focus on the EV/Capital Employed ratio of 1.40 times, which indeed looks reasonable. However, this metric alone cannot override the fundamental concern that capital employed is generating minimal returns.

Given the quality of earnings concerns, deteriorating return metrics, and lack of dividend support, a fair value estimate would place the stock closer to ₹18-20 per share, implying 20-28% downside from current levels. This estimate assumes normalisation of other income contribution and modest improvement in operating margins, neither of which appears imminent based on recent quarterly trends.

Shareholding Pattern: Stable but Uninspiring Institutional Interest

The shareholding pattern of Primo Chemicals reveals a promoter group maintaining a 32.40% stake as of March 2026, with a marginal 1.05% increase from 31.35% in the December 2025 quarter. This uptick, whilst modest, signals promoter confidence or potentially a strategic consolidation move. Key promoters include Sukhbir Singh Dahiya (10.43%), Jagbir Singh Ahlawat (6.40%), and Flowtech Industrial Projects Private Limited (5.01%), amongst others. Importantly, there is no pledging of promoter shares, eliminating concerns about financial stress at the promoter level.

However, the institutional interest in Primo Chemicals remains conspicuously anaemic. Foreign institutional investors hold a negligible 0.08%, mutual funds maintain a static 1.90%, and insurance companies have zero exposure. The total institutional holding of merely 2.00% speaks volumes about the lack of conviction amongst sophisticated investors who conduct rigorous fundamental analysis before deploying capital. With 11 mutual funds holding positions but collectively accounting for less than 2% of equity, the average fund holding is minuscule, suggesting token exposure rather than high-conviction bets.

The dominance of non-institutional shareholders at 65.60% indicates a retail-heavy shareholder base, which can contribute to higher volatility and potentially less informed trading patterns. The absence of meaningful institutional accumulation despite the stock's "Attractive" valuation grade raises questions about whether professional investors see fundamental concerns that valuation metrics alone do not capture. The marginal decline in non-institutional holdings from 66.65% in September 2025 to 65.60% in March 2026 suggests some retail profit-taking or loss of patience.

Stock Performance: Decade of Extremes

Primo Chemicals' stock price trajectory over various timeframes presents a study in contrasts, with extraordinary long-term gains masking recent underperformance. Over the past decade, the stock has delivered a staggering 864.70% return, dramatically outpacing the Sensex's 205.90% gain by an alpha of 658.80 percentage points. This exceptional performance reflects the company's transformation and expansion over the 2010s, though much of this gain occurred in earlier years.

However, the medium-term picture is far less flattering. Over the past three years, the stock has plummeted 66.05%, underperforming the Sensex by a devastating 92.45 percentage points. The two-year return of -41.63% versus the Sensex's +4.44% reflects the sustained pressure on the stock as operational challenges mounted and earnings quality deteriorated. Even over the past year, the stock's 1.09% gain, whilst positive in absolute terms, underperformed the commodity chemicals sector's 11.88% return by 10.79 percentage points.

The recent momentum, however, shows signs of reversal. Over the past week, the stock surged 10.17%, outpacing the Sensex by 10.58 percentage points, whilst the one-month and three-month returns of 11.73% and 13.76% respectively demonstrate renewed investor interest. This short-term outperformance coincides with the Q4 results announcement, suggesting the market is responding positively to the sequential improvement in profitability, albeit with the caveats discussed earlier regarding earnings quality.

Technical indicators paint a mixed picture. The stock currently trades above all major moving averages—5-day (₹24.12), 20-day (₹23.58), 50-day (₹20.67), 100-day (₹21.48), and 200-day (₹23.38)—suggesting technical strength. However, the overall trend classification remains "Sideways" as of May 05, 2026, having shifted from "Mildly Bearish" just a day earlier. The high beta of 1.50 indicates significantly greater volatility than the broader market, with annualised volatility of 44.45% classifying the stock as "High Risk Medium Return."

Investment Thesis: Quality Concerns Override Valuation Appeal

The investment case for Primo Chemicals rests on a precarious balance between valuation metrics that appear superficially attractive and fundamental quality indicators that raise persistent concerns. The company's Mojo score of 64 out of 100 places it in "HOLD" territory, upgraded from "SELL" just a day prior, reflecting the market's attempt to reconcile the Q4 profitability recovery with longer-term structural challenges.

Breaking down the investment parameters reveals the complexity. The valuation grade of "Very Attractive" focuses on metrics like EV/Capital Employed of 1.40 times and the recent stock price correction from 52-week highs. However, this attractiveness must be weighed against a quality grade that has oscillated between "Good" and "Average," with the current "Good" classification appearing generous given the ROCE of just 4.78% and ROE of 2.54%. The financial trend is classified as "Positive" based on sequential quarterly improvement, but this ignores the concerning nine-month decline in profitability.

The technical trend of "Sideways" adds further uncertainty, suggesting the market itself is undecided about the stock's direction. For investors, the key question becomes whether the Q4 sequential recovery represents a genuine inflection point or merely a temporary respite in a longer-term deterioration. The evidence leans towards the latter interpretation, given that year-on-year comparisons remain weak and the dependency on other income has actually intensified rather than diminished.

Key Strengths & Risk Factors

Outlook: What to Watch